Dengue Vaccine Eligibility Expanded to Ages 4 and Up in Presidente Prudente
The dengue vaccination program in Presidente Prudente, São Paulo, has been expanded to include individuals aged 4 and older, effective Tuesday, February 21st. This temporary measure aims to prevent the wastage of vaccine doses nearing their expiration date. The expanded eligibility applies to the Qdenga vaccine, following guidance from the Ministry of Health, and will be administered at Basic Health Units (UBSs) to individuals between 4 and 59 years old. Previously, the National Immunization Program (PNI) only offered the vaccine to children and adolescents aged 10 to 14. The current expansion specifically targets doses with an expiration date of August 21, 2026. This allows individuals from 4 years up to 59 years, 11 months, and 29 days to receive their first dose, provided these specific doses are available across the municipality's 27 vaccination sites. To date, 7,348 people in Presidente Prudente have received their first dose of the Qdenga vaccine, and 4,957 have completed the vaccination schedule with their second dose.
The temporary expansion of dengue vaccine eligibility in Presidente Prudente highlights a common challenge in public health campaigns: managing vaccine supply and expiration dates. By broadening the recipient age range, health authorities aim to maximize the utility of available doses, thereby optimizing resource allocation. This approach underscores the dynamic nature of vaccine deployment, which must balance public health goals with logistical realities. Looking ahead, such strategies may inform future vaccination drives, particularly as new vaccines become available and the need for efficient distribution grows in an era of evolving public health threats.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.